Gapping up
In reaction to strong earnings/guidance: HIHO +15.9%, FLWS +7.7%, LII +2.8%, SYY +1.9%, NMM +1.4%, XOM +0.5%
M&A news: CRH +4.8% (Holcim (HCLMY) and Lafarge (LFRGY) announce a project to sell assets to CRH for an enterprise value of EUR 6.5 bln in the context of their planned merger)
Select oil/gas related names showing strength: SDRL +4.1%, STO +3.7%, TOT +2.7%, LINE +2.5%, SSL +2.4%, OAS +1.5%, OXY +1.5%, RDS.A +1.1%, HAL +1%, RIG +0.9%
Other news: MCP +20.9% (reported that rare earth production in the fourth quarter of 2014 at its Mountain Pass, California facility increased y/y and nearly doubled that of the preceding quarter), CAMT +12.1% (selected by a leading semiconductor manufacturer as the supplier of choice to provide systems for defect detection and metrology of advanced packaging applications), FRO+10.4% (provides capital update), ZGNX +9.6% (receives FDA approval of new formulation of Zohydro ER), NBG +9.1% (Greece PM speech over wkend implying cooperation with EU), BLUE +8.1% (FDA grants "Breakthrough Therapy Designation" to LentiGlobin for treatment of beta-thalassemia major), GST +6.8% (announces 87% increase in proved reserves), KMDA +5.5% (reports additional data from its open-label Phase 1/2 trial of IV Alpha1-Proteinase Inhibitor--Human), SANW +5.1% (files for ~13.3 mln share common stock offering by selling shareholders), EXXI +4.4% (still checking), AMD +4.3% (positive Barron's mention), BGMD +3.8% (receipt of favorable NASDAQ Listing Determination; exchange granted its request for continued listing), CTSO +3.5% (FDA approval to commence initial U.S. cardiac surgery study), SN +2.6% (Q4 daily avg. production at high end of guidance), MYL +2.1% (Theravance Biopharma and Mylan partner to develop and commercialize a novel LAMA compound), ALLT +1.9% (launches cloud access optimization solution with Microsoft (MSFT) Office 365 Support ), RDUS +1.7% (initiated with a Buy at BofA/Merrill),GPRO +1.0% (Chairman/CEO Nicholas Woodman discloses 44.9% stake in the company), CNI +0.8% (announces plan to buy back 1.2 mln shares through a private agreement), SHPG +0.8% (Vyvanse capsules becomes first and only treatment approved by the FDA for adults with moderate to severe binge eating disorder)
Analyst comments: DEG +2.5% (upgraded to Buy at Jefferies), DECK +2.2% (upgraded to Buy at Goldman), M +1.7% (initiated with a Buy at Evercore ISI), FUN +1.3% (upgraded to Buy at Goldman), CAM +0.5% (upgraded to Overweight at Barclays)
In reaction to strong earnings/guidance: HIHO +15.9%, FLWS +7.7%, LII +2.8%, SYY +1.9%, NMM +1.4%, XOM +0.5%
M&A news: CRH +4.8% (Holcim (HCLMY) and Lafarge (LFRGY) announce a project to sell assets to CRH for an enterprise value of EUR 6.5 bln in the context of their planned merger)
Select oil/gas related names showing strength: SDRL +4.1%, STO +3.7%, TOT +2.7%, LINE +2.5%, SSL +2.4%, OAS +1.5%, OXY +1.5%, RDS.A +1.1%, HAL +1%, RIG +0.9%
Other news: MCP +20.9% (reported that rare earth production in the fourth quarter of 2014 at its Mountain Pass, California facility increased y/y and nearly doubled that of the preceding quarter), CAMT +12.1% (selected by a leading semiconductor manufacturer as the supplier of choice to provide systems for defect detection and metrology of advanced packaging applications), FRO+10.4% (provides capital update), ZGNX +9.6% (receives FDA approval of new formulation of Zohydro ER), NBG +9.1% (Greece PM speech over wkend implying cooperation with EU), BLUE +8.1% (FDA grants "Breakthrough Therapy Designation" to LentiGlobin for treatment of beta-thalassemia major), GST +6.8% (announces 87% increase in proved reserves), KMDA +5.5% (reports additional data from its open-label Phase 1/2 trial of IV Alpha1-Proteinase Inhibitor--Human), SANW +5.1% (files for ~13.3 mln share common stock offering by selling shareholders), EXXI +4.4% (still checking), AMD +4.3% (positive Barron's mention), BGMD +3.8% (receipt of favorable NASDAQ Listing Determination; exchange granted its request for continued listing), CTSO +3.5% (FDA approval to commence initial U.S. cardiac surgery study), SN +2.6% (Q4 daily avg. production at high end of guidance), MYL +2.1% (Theravance Biopharma and Mylan partner to develop and commercialize a novel LAMA compound), ALLT +1.9% (launches cloud access optimization solution with Microsoft (MSFT) Office 365 Support ), RDUS +1.7% (initiated with a Buy at BofA/Merrill),GPRO +1.0% (Chairman/CEO Nicholas Woodman discloses 44.9% stake in the company), CNI +0.8% (announces plan to buy back 1.2 mln shares through a private agreement), SHPG +0.8% (Vyvanse capsules becomes first and only treatment approved by the FDA for adults with moderate to severe binge eating disorder)
Analyst comments: DEG +2.5% (upgraded to Buy at Jefferies), DECK +2.2% (upgraded to Buy at Goldman), M +1.7% (initiated with a Buy at Evercore ISI), FUN +1.3% (upgraded to Buy at Goldman), CAM +0.5% (upgraded to Overweight at Barclays)